2025 Regulatory Year in Review: Cost Savings, Energy Shifts, and What to Watch in 2026

Introduction: The 2025 Regulatory Pivot

The Trump administration’s return to the White House in 2025 brought an immediate and forceful shift in federal regulatory philosophy. Building on the deregulatory momentum of its first term, the administration moved to tighten rulemaking procedures across the executive branch, requiring agencies to submit stronger economic justifications for any new regulations. This was not merely a continuation of past policies; it represented a structural reengineering of how federal rules are proposed, reviewed, and implemented. The message was clear: every new rule must prove its necessity, and the default presumption shifted against regulatory expansion.

The primary analytical lens for understanding this transformation comes from the George Washington University Regulatory Studies Center’s 2025 Regulatory Year in Review, which catalogued the year’s major procedural and substantive changes. Complementing that academic assessment, the Office of Management and Budget (OMB) reported a staggering $211.8 billion in net regulatory cost savings for fiscal year 2025 — one of the largest single-year reductions ever recorded. As Nicholas Huff of Americans for Prosperity noted in his analysis of the GWU and OMB data, the figure reflects not just the elimination of existing rules but also the prevention of costly new ones that would have taken effect under a less stringent oversight regime.

This article serves a dual purpose. First, it recaps the most consequential 2025 regulatory developments — from strengthened oversight to energy deregulation and healthcare reforms. Second, it previews three high-stakes areas that will define 2026: legal battles over executive authority, permitting reform legislation, and mounting healthcare cost pressures. For policymakers, industry stakeholders, and legal professionals navigating this rapidly shifting landscape, understanding what happened in 2025 is essential to anticipating what comes next.

[IMAGE: A split graphic showing a stack of red-tape documents on the left and a clear, streamlined flowchart on the right, symbolizing deregulation.]

Strengthened Oversight and the $211.8 Billion Savings

The cornerstone of the 2025 regulatory agenda was a dramatic escalation in executive oversight of rulemaking. Early in the year, the White House issued an executive order requiring all federal agencies to conduct rigorous cost-benefit analyses for any proposed rule with an annual economic impact exceeding $100 million. Agencies were further instructed to justify why market-based alternatives or state-level solutions would not suffice before pursuing federal action. For rules that survived initial scrutiny, OMB’s Office of Information and Regulatory Affairs (OIRA) was granted expanded authority to delay, modify, or reject submissions that failed to meet the new evidentiary standards.

These procedural changes were not merely administrative niceties. According to the GWU Regulatory Studies Center’s year-end review, the number of economically significant rules published in the Federal Register dropped by more than 35% compared to the 2020–2024 average. Agencies that had grown accustomed to proposing rules with speculative benefits and inflated cost estimates found themselves required to produce peer-reviewed data and transparent modeling. The result was a dramatic slowdown in the rulemaking pipeline — a slowdown that the administration framed not as bureaucratic gridlock but as disciplined governance.

The OMB’s $211.8 billion net cost savings figure is derived from comparing the estimated costs of rules that were withdrawn, delayed, or never proposed against the costs of rules that were finalized. In historical context, the 2025 reduction surpasses even the most aggressive deregulatory years of the first Trump term, when net savings peaked at roughly $100 billion annually. Critics argue that the metric overstates savings by ignoring the social costs of regulatory rollbacks — for example, reduced environmental protections or weakened consumer safeguards. Yet the sheer scale of the number underscores a central political reality: the administration is willing to absorb those criticisms in pursuit of what it calls “economic liberation from overregulation.”

[IMAGE: Bar chart comparing annual regulatory costs before and after 2025, with a callout for $211.8B.]

Energy and the Environment: Domestic Production Takes Center Stage

Nowhere was the 2025 regulatory pivot more visible than in energy and environmental policy. The administration pursued an aggressive agenda to boost domestic production of oil, natural gas, and critical minerals, while simultaneously scaling back climate-focused rules that had been prioritized by the previous administration. Key changes included streamlined permitting for drilling on federal lands, expedited approval of natural gas export terminals, and the removal of methane emission reporting requirements for upstream oil and gas operators. At the same time, the Department of the Interior revised its five-year offshore leasing program to include more frequent auctions in the Gulf of Mexico and Alaska.

Perhaps the most consequential move was the overhaul of the National Environmental Policy Act (NEPA) implementation guidance. The Council on Environmental Quality issued new rules that shortened environmental review timelines for major infrastructure projects from an average of 4.5 years to less than 18 months, limiting the scope of required impact statements and allowing agencies to rely on existing environmental data rather than conducting new studies. This permitting reform logic — faster approvals at the cost of less comprehensive environmental analysis — was extended to renewable energy projects as well, with the Bureau of Land Management accelerating approvals for solar and wind installations on public lands.

The trade-offs are stark. Industry groups celebrated the reduction in regulatory uncertainty, noting that energy-intensive sectors such as manufacturing, data centers, and chemical processing saw supply chain bottlenecks ease as domestic fuel and feedstock prices stabilized. Environmental organizations, however, warned that the rapid approvals would lead to long-term ecological damage and undermine U.S. commitments under the Paris Agreement. The GWU review highlighted a critical tension: while the administration’s focus on production and infrastructure permitting served a clear economic logic — lower energy costs and greater energy independence — it also set the stage for protracted litigation over the legality of reduced environmental reviews. Several lawsuits filed by state attorneys general and conservation groups in late 2025 are expected to reach federal appeals courts in 2026.

[IMAGE: Map of the U.S. with icons for oil wells, wind turbines, and pipelines, overlaid with a 'Permit Approved' stamp.]

Healthcare Regulation: Cost, Competition, and Domestic Manufacturing

Healthcare regulation in 2025 reflected a parallel emphasis on cost reduction and market competition. The administration advanced a series of policies aimed at lowering drug prices, increasing biosimilar adoption, and repatriating pharmaceutical manufacturing to U.S. soil. At the center of these efforts was the FDA’s accelerated approval pathway for biosimilars, which the agency streamlined by reducing the number of required clinical trials for products that could demonstrate similarity to an existing biologic. The move was intended to inject competition into the $500 billion biologics market, where originator companies have long used patent thickets and regulatory complexity to delay lower-cost alternatives.

On the pricing front, the administration expanded the use of international reference pricing for Medicare Part B and Part D drugs, tying reimbursement rates to the average price paid in other developed countries. This policy, which had been debated for years but never fully implemented, drew sharp opposition from pharmaceutical companies and some patient advocacy groups who argued it would stifle innovation. Nevertheless, the Congressional Budget Office estimated that the reference pricing mechanism would save Medicare $45 billion over the next decade.

Equally significant were the incentives for domestic manufacturing. The administration used executive authority to classify active pharmaceutical ingredients (APIs) as critical national security materials, making drug manufacturing facilities eligible for expedited permitting and tax credits under the Defense Production Act. Several major pharmaceutical firms announced plans to build or expand API production plants in Texas, Ohio, and South Carolina, citing the improved regulatory environment as a key factor in their investment decisions.

Yet these reforms brought their own legal vulnerabilities. The reference pricing policy is currently facing a constitutional challenge from the Pharmaceutical Research and Manufacturers of America (PhRMA), which argues that it violates the Fifth Amendment’s takings clause by effectively confiscating intellectual property value. Meanwhile, the FDA’s biosimilar streamlining is being litigated over whether the agency exceeded its statutory authority by relaxing safety and efficacy standards. These cases will be closely watched in 2026 as bellwethers for the limits of executive-driven healthcare deregulation.

[IMAGE: A split illustration showing a downward-trending drug price chart on one side and a pharmaceutical manufacturing plant with an American flag on the other.]

Looking Ahead: Three Critical Areas for 2026

As the regulatory landscape settles into its new contours, three areas demand close attention in 2026.

First, legal challenges to executive authority. The string of lawsuits targeting EPA’s methane rule rollback, FDA’s biosimilar changes, and OMB’s cost-benefit requirements will test the administration’s ability to sustain its deregulatory agenda through the courts. A key question is whether the Supreme Court’s recent curtailment of the Chevron doctrine will embolden lower courts to strike down agency interpretations that depart from statutory language. The outcome of these cases could either reinforce the 2025 pivot or force the administration to seek legislative cover for its most aggressive moves.

Second, permitting reform legislation. While the executive branch made significant progress through NEPA guidance and agency actions, comprehensive permitting reform — covering energy, infrastructure, and manufacturing — remains stalled in Congress. Bipartisan negotiations have centered on a package that would set statutory deadlines for environmental reviews, limit standing for certain types of lawsuits, and create a centralized permitting dashboard. Whether such a bill can overcome filibuster hurdles and interest-group opposition in an election year will be a defining test of the administration’s legislative strategy.

Third, mounting healthcare cost pressures. Despite the 2025 reforms, healthcare remains the single largest driver of household and federal budget strain. With Medicare trust fund exhaustion projected to accelerate by 2028, the pressure to achieve deeper cost savings will intensify. The administration may push for additional measures such as importation of lower-cost drugs from Canada, tighter restrictions on pharmacy benefit manager (PBM) practices, or even price caps on certain high-cost gene therapies. Any of these would spark fierce political and legal battles, but the arithmetic of an aging population leaves little room for inaction.

[IMAGE: Timeline graphic from 2025 to 2026 with icons: a gavel, an oil derrick, a pill bottle, and a scale of justice, moving along an upward path.]

---

The 2025 regulatory year was defined by deliberate, aggressive cost savings and a reorientation toward domestic production. The $211.8 billion net reduction reported by OMB, while contested in methodology, signals a policy direction that is unlikely to reverse regardless of which party controls Congress after 2026. For industry stakeholders, the immediate task is to adapt to the new rulemaking paradigm — where procedural rigor is high but substantive regulation is low — while preparing for the legal and legislative battles that will shape the next phase. For policymakers, the challenge is to prove that deregulation can deliver sustainable economic growth without sacrificing the public protections that voters continue to demand. The year ahead will be a stress test for both sides of that equation.